ReviewCurrent neurology and neuroscience reports2014
Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.
Review in Current neurology and neuroscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Long-term forgetting, sleep, and tau in autosomal-dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.Frontiers in aging neuroscience · 2026Article
- Regional cortical network atrophy predicts progression to dementia in the Lewy body diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co-Pathology in Lewy Body Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.Neurology · 2024Observational
- Lewy Body Dementias: A Coin with Two Sides?Behavioral sciences (Basel, Switzerland) · 2021Review
- Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.Alzheimer's research & therapy · 2020Review
- Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.European archives of psychiatry and clinical neuroscience · 2020Article
- Topography of cortical thinning in the Lewy body diseases.NeuroImage. Clinical · 2020Article
- Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.Neurology · 2019Article
- Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson's Disease.Journal of Parkinson's disease · 2019Article
- Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Article
- Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms.Journal of movement disorders · 2018Review
- Interactions of pathological proteins in neurodegenerative diseases.Acta neuropathologica · 2017Review
- Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.F1000Research · 2017Review
- Cystatin C in aging and in Alzheimer's disease.Ageing research reviews · 2016Review
- Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.JAMA neurology · 2016Article
- Arguing against the proposed definition changes of PD.Movement disorders : official journal of the Movement Disorder Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment and dementia are significant sequelae of Parkinson disease (PD) and comprise a key feature of dementia with Lewy bodies (DLB), a disease with similar clinical and neuropathological features. Multiple independent causes have been implicated in PD dementia (PDD) and DLB, among them the accumulation of β-amyloid, a neuropathological hallmark of Alzheimer disease. Over the last decade, PET imaging has emerged as a viable method to measure amyloid burden in the human brain and relate it to neurodegenerative diseases. This article reviews what amyloid imaging has taught us about PDD and DLB. Current data suggest that brain amyloid deposition tends to be more marked in DLB, yet contributes to cognitive impairment in both DLB and PD. These results are broadly consistent with neuropathology and CSF studies. β-Amyloid may interact synergistically with other pathological processes in PD and DLB to contribute to cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.